Skip to content

Punarnava Arka preparation and clinical trial in Allergic conjuntivitis

Evaluate the effect of punarnava arka in simple allergic conjunctivitis - a randomised controlled clinical trial - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076491
Enrollment
50
Registered
2024-11-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H109- Unspecified conjunctivitis

Interventions

Intervention1: PUNARNAVA ARKA: 1 Drop 6 times a day Topical for 21 days Control Intervention1: Eyedrop Olopatadine Hydrochloride Ophthalmic Solution Ip 0.1%: 1 Drop 2 times a day (Topical) for 21 day

Sponsors

Dr Mahore Akash Manohar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients presenting with signs and symptoms of Simple Allergic Conjunctivitis and fulfilling the diagnostic criteria

Exclusion criteria

Exclusion criteria: Patients suffering from other forms Allergic Conjunctivitis like Keratoconjunctivitis sicca Atopic keratoconjunctivitis Giant papillary conjunctivitis drug or material sensitivity etc Patients having severe conditions of ocular surface disorders Patients having complicated eye diseases like Trachoma Trichiasis Steven Johnson syndrome Synechiae etc will be excluded Patient suffering from bacterial viral chlamydial, parasitic and all other types of conjunctivitis (contagious & non contagious) Patients suffering from corneal ulcers opacities trauma foreign bodies OSD etc Conjunctival epitheliopathies like Pterygium Pseudo-pterygium Tumours Retention cysts Diagnosed cases of Glaucoma retinopathies optic neuritis dry eye and who are under long term topical ocular drug therapies for any ophthalmic infective conditions Extremely debilitated patients pregnant ladies those who are working with on screen professions Specific systemic disorders like Renal pathologies Uncontrolled Diabetes Hypertension and Hyperlipidaemia Cardiovascular diseases etc

Design outcomes

Primary

MeasureTime frame
The results of reduction in signs and symptoms of itching, redness, watering and oedema by Punarnava Arka and Eyedrop Olopatadine Hydrochloride ophthalmic soltion IP 0.1 percent are comparable.Timepoint: DAY 0th(Before Treatment) DAY 21(After Treatment) DAY 36(Follow Up)

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Arunkumar B Biradar

KAHERs Shri BMK Ayurveda Mahavidyalaya, Shahapur, BELAGAVI, Karnataka, INDIA

arunkumar.biradar@gmail.com9964064955

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026